Bayer opens research center in Boston for USD 140 million | news

news-container">

shares in this article

FRANKFURT (Dow Jones)–Bayer is opening another research and innovation center in the United States. As the DAX group announced, the total investment for the center amounts to 140 million US dollars. The aim is to advance the development of novel, targeted cancer therapies there.

The 5,700 square meter building on Kendall Square in Boston-Cambridge houses a precision molecular oncology research center. It will have a newly established research team that will use chemical-biological technologies in a targeted manner to advance Bayer’s development processes for oncological drugs. The center offers space for 100 employees on two floors. Bayer plans to add 50 more jobs in the coming months.

Contact the author: [e-mail]

DJG/mgo/ros

(END) Dow Jones Newswires

June 29, 2022 08:00 ET (12:00 GMT)

Selected leverage products on BayerWith knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired lever and we will show you suitable open-end products on Bayer

Leverage must be between 2 and 20

No data